Immunosuppressants for therapy of patients with ulcerative colitis

Tadakazu Hisamatsu, Toshifumi Hibi

Research output: Contribution to journalReview article

Abstract

Ulcerative colitis (UC) has been known as inflammatory bowel disease. Progress in UC management strategies has led to optimized approaches for achieving the two primary clinical goals of therapy: induction and maintenance of remission. We here review about immunosuppressants in management of UC; Cyclosporine A (CsA) has been used for the induction therapy in steroid resistant refractory UC. Although it has been reported that CsA has high response rate in severe UC, long-term efficacy (maintenance of remission) has not been proven. To improve maintenance therapy, immunosuppressant has been re-considered in management of UC. In recent years, it has been reported that efficacy of 6-mercaptopurine/azathioprine in maintenance of remission of UC is superior to 5-aminosalicylate (5-ASA). Pharmacological studies have indicated thiopurine methyltransferase (TPMT) activity is essential for maintenance of blood concentration of 6-thioguanine nucleotide (6-TG).

Original languageEnglish
Pages (from-to)831-835
Number of pages5
JournalNippon rinsho. Japanese journal of clinical medicine
Volume63
Issue number5
Publication statusPublished - 2005 May

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Immunosuppressants for therapy of patients with ulcerative colitis'. Together they form a unique fingerprint.

  • Cite this